- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03571256
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS) (ARTISTS2)
November 5, 2021 updated by: Teva Branded Pharmaceutical Products R&D, Inc.
A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome
Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
158
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina, C1023AAB
- Teva Investigational Site 060-1407
-
Buenos Aires, Argentina, C1425AHQ
- Teva Investigational Site 060-1402
-
Buenos Aires, Argentina, C1058AAJ
- Teva Investigational Site 060-1401
-
La Plata, Argentina, 1900
- Teva Investigational Site 060-1403
-
Mendoza, Argentina, 5500
- Teva Investigational Site 060-1404
-
-
-
-
-
Liverpool, Australia, 2170
- Teva Investigational Site 060-1802
-
Parkville, Australia, 3052
- Teva Investigational Site 060-1801
-
-
-
-
-
Bello, Colombia, 051050
- Teva Investigational Site 060-1503
-
Medellin, Colombia, 5500515
- Teva Investigational Site 060-1501
-
Medellin, Colombia, 78 B 50
- Teva Investigational Site 060-1506
-
Pereira, Colombia, 660003
- Teva Investigational Site 060-1504
-
-
-
-
-
Budapest, Hungary, 1021
- Teva Investigational Site 060-0901
-
Szeged, Hungary, 6725
- Teva Investigational Site 060-0902
-
-
-
-
-
Cagliari, Italy, 09121
- Teva Investigational Site 060-1005
-
Catania, Italy, 95123
- Teva Investigational Site 060-1001
-
Naples, Italy, 80131
- Teva Investigational Site 060-1003
-
Rome, Italy, 00165
- Teva Investigational Site 060-1004
-
-
-
-
-
Seoul, Korea, Republic of, 110-744
- Teva Investigational Site 060-1901
-
Seoul, Korea, Republic of, 138-736
- Teva Investigational Site 060-1903
-
Seoul, Korea, Republic of, 6351
- Teva Investigational Site 060-1902
-
Seoul, Korea, Republic of, 3722
- Teva Investigational Site 060-1904
-
-
-
-
-
Culiacan, Mexico, 80020
- Teva Investigational Site 060-1601
-
Leon, Mexico, 37000
- Teva Investigational Site 060-1603
-
Monterrey, Mexico, 64460
- Teva Investigational Site 060-1602
-
Monterrey, Mexico, 64610
- Teva Investigational Site 060-1604
-
-
-
-
-
Gdansk, Poland, 80-542
- Teva Investigational Site 060-1104
-
Katowice, Poland, 40-123
- Teva Investigational Site 060-1101
-
Krakow, Poland, 31503
- Teva Investigational Site 060-1105
-
Poznan, Poland, 60-693
- Teva Investigational Site 060-1102
-
Torun, Poland, 87-100
- Teva Investigational Site 060-1106
-
Warsaw, Poland, 02-793
- Teva Investigational Site 060-1103
-
-
-
-
-
Dnipropetrovsk, Ukraine, 49101
- Teva Investigational Site 060-2003
-
Kharkiv, Ukraine, 61068
- Teva Investigational Site 060-2001
-
Kharkiv, Ukraine, 61153
- Teva Investigational Site 060-2002
-
Kiev, Ukraine, 4080
- Teva Investigational Site 060-2007
-
Kyiv, Ukraine, 4209
- Teva Investigational Site 060-2005
-
Vinnytsia, Ukraine, 21005
- Teva Investigational Site 060-2006
-
-
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Teva Investigational Site 060-0160
-
Gulf Breeze, Florida, United States, 32561-4458
- Teva Investigational Site 060-0166
-
Miami, Florida, United States, 33136-2107
- Teva Investigational Site 060-0161
-
Orlando, Florida, United States, 32819
- Teva Investigational Site 060-0153
-
Orlando, Florida, United States, 32801
- Teva Investigational Site 060-0151
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Teva Investigational Site 060-0168
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Teva Investigational Site 060-0155
-
Chicago, Illinois, United States, 60634
- Teva Investigational Site 060-0164
-
-
Indiana
-
Indianapolis, Indiana, United States, 46256
- Teva Investigational Site 060-0152
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Teva Investigational Site 060-0158
-
-
Maryland
-
Rockville, Maryland, United States, 20852-4219
- Teva Investigational Site 060-0167
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Teva Investigational Site 060-0165
-
-
Missouri
-
Bridgeton, Missouri, United States, 63044
- Teva Investigational Site 060-0170
-
-
New York
-
New York, New York, United States, 10036
- Teva Investigational Site 060-0154
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414-5834
- Teva Investigational Site 060-0169
-
-
Tennessee
-
Memphis, Tennessee, United States, 38157
- Teva Investigational Site 060-0157
-
Nashville, Tennessee, United States, 37232-2551
- Teva Investigational Site 060-0156
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Teva Investigational Site 060-0163
-
-
Washington
-
Everett, Washington, United States, 98201-4077
- Teva Investigational Site 060-0162
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 16 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant weighs at least 44 pounds (20 kg) at baseline.
- Participant meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5™) diagnostic criteria for TS and, in the opinion of the investigator, participant, and parent/legal guardian, the participant's active tics are causing distress or impairment.
- Participant has a TTS of 20 or higher on the YGTSS at screening and baseline.
- Participant is able to swallow study medication whole.
- -Additional criteria apply, please contact the investigator for more information
Exclusion Criteria:
- Participant has a neurologic disorder other than TS that could obscure the evaluation of tics.
- The participant 's predominant movement disorder is stereotypy (coordinated movements that repeat continually and identically) associated with autism spectrum disorder.
- Participant has clinically significant depression at screening or baseline.
- Participant has a history of suicidal intent or related behaviors within 2 years of screening
- Participant has a history of a previous actual, interrupted, or aborted suicide attempt.
- Participant has a first-degree relative who has completed suicide.
- Participant has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder.
- Participant has received Comprehensive Behavioral Intervention for Tics for TS or Cognitive Behavioral Therapy for obsessive-compulsive disorder (OCD) within 4 weeks of screening.
- Participant has received treatment with deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation within 4 weeks of the screening visit for reduction of tics.
- Participant has a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure.
- Participant has participated in an investigational drug or device study and received investigational medicinal product (IMP)/intervention within 30 days or 5 drug half-lives of baseline, whichever is longer.
- Participant is a pregnant or lactating female, or plans to be pregnant during the study.
- -Additional criteria apply, please contact the investigator for more information
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TEV-50717 High-Dose
TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks
|
6-, 9-, 12-, 15-, and 18 mg oral tablets
Other Names:
Placebo matched to TEV-50717 tablets will be taken BID.
|
Experimental: TEV-50717 Low-Dose
TEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks
|
6-, 9-, 12-, 15-, and 18 mg oral tablets
Other Names:
Placebo matched to TEV-50717 tablets will be taken BID.
|
Placebo Comparator: Placebo
Placebo matched to TEV-50717 for a total of 8 weeks
|
Placebo matched to TEV-50717 tablets will be taken BID.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
Time Frame: Baseline, Week 8
|
YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics.
YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment.
Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe).
MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity.
TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe).
Higher scores indicate greater severity/worse outcome.
Least square (LS) mean and standard error (SE) was calculated using mixed-model repeated-measures (MMRM) with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.
|
Baseline, Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
Time Frame: Baseline, Week 8
|
The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life.
The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics).
Lower scores indicate better quality of life.
LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.
|
Baseline, Week 8
|
Change From Baseline in the TTS of the YGTSS at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
Time Frame: Baseline, Week 8
|
YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics.
YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment.
Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe).
MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity.
TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe).
Higher scores indicate greater severity/worse outcome.
LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.
|
Baseline, Week 8
|
Change From Baseline in the TS-CGI Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
Time Frame: Baseline, Week 8
|
The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life.
The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics).
Lower scores indicate better quality of life.
LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.
|
Baseline, Week 8
|
Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
Time Frame: Baseline, Week 8
|
The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?).
The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy.
|
Baseline, Week 8
|
Change From Baseline in the TS-PGII Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
Time Frame: Baseline, Week 8
|
The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?).
The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy.
|
Baseline, Week 8
|
Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
Time Frame: Baseline, Week 8
|
C&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms.
C&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem.
Following 3 questions from 27-item questionnaire were assessed in ADL C&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?).
Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem).
Lower score indicated better quality of life.
LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates.
|
Baseline, Week 8
|
Change From Baseline in the C&A-GTS-QOL ADL Subscale Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants
Time Frame: Baseline, Week 8
|
C&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms.
C&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem.
Following 3 questions from 27-item questionnaire were assessed in ADL C&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?).
Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem).
Lower score indicated better quality of life.
LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates.
|
Baseline, Week 8
|
Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version and Self-reported Version) Total Score at Week 9
Time Frame: Baseline, Week 9
|
CDI-2 self-report: 28-item questionnaire assessing depressive symptoms in children 7 to 17 years of age with basic reading and comprehension skills.
Children were asked to choose 1 of 3 statements that most closely aligns with their feelings in past 2 weeks.
It contains 6 subscales (emotional problem, negative mood/physical symptoms, negative self-esteem, functional problems, ineffectiveness, interpersonal problems).
Total score: sum of all subscales scores, ranging from 0 to 56, with higher score indicating greater depression severity.CDI-2 parent: 17-item questionnaire administered to parents to assess depression-related behaviors observed in their children.
Parents were asked to rate their child's behaviors in past 2 weeks on a 4-point Likert scale from "not at all" to "much or most of the time."
It contains 2 subscales (emotional problems and functional problem).
Total score: sum of 2 subscales, ranging from 0 to 51, with higher score indicating more depression-related behaviors.
|
Baseline, Week 9
|
Number of Participants at Baseline and Week 9 With Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: Baseline, Week 9
|
C-SSRS included responses for Suicidal Ideation or Suicidal Behavior in following 10 categories: 1 = Wish to be dead; 2 = Non-specific active suicidal thoughts; 3 = Active suicidal ideation with any methods (not plan) without intent to act; 4 = Active suicidal ideation with some intent to act, without specific plan; 5 = Active suicidal ideation with specific plan and intent; 6 = Preparatory acts or behavior; 7 = Aborted attempt; 8 = Interrupted attempt; 9 = Non-fatal suicide attempt; and 10 = Completed suicide.
Number of participants with any suicidal ideation or suicidal behavior are reported.
Any Suicidal ideation or Suicidal Behavior events reported as TEAEs along with all other reported TEAEs are included in the AE module.
|
Baseline, Week 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 31, 2018
Primary Completion (Actual)
December 9, 2019
Study Completion (Actual)
December 9, 2019
Study Registration Dates
First Submitted
June 18, 2018
First Submitted That Met QC Criteria
June 18, 2018
First Posted (Actual)
June 27, 2018
Study Record Updates
Last Update Posted (Actual)
November 9, 2021
Last Update Submitted That Met QC Criteria
November 5, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Disease
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Neurodevelopmental Disorders
- Tic Disorders
- Syndrome
- Tourette Syndrome
Other Study ID Numbers
- TV50717-CNS-30060
- 2017-002976-24 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan.
Requests will be reviewed for scientific merit, product approval status, and conflicts of interest.
Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information.
Please email USMedInfo@tevapharm.com to make your request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tourette Syndrome
-
Children's Hospital Medical Center, CincinnatiTourette Association of AmericaRecruitingTourette Syndrome | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Tourette Syndrome, Modifier ofUnited States
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Ministry of Health, ItalyCompletedTourette Syndrome | Tourette's Syndrome | Tourette Disorder | Gilles de la Tourette SyndromeItaly
-
Tasly Pharmaceuticals, Inc.Not yet recruitingTourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States
-
Emalex Biosciences Inc.CompletedTourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States, Poland, France, Canada, Germany
-
Vanderbilt University Medical CenterCompletedTourette Syndrome | Tourette Syndrome in Children | Tourette Syndrome in AdolescenceUnited States
-
Johns Hopkins UniversityCompletedTourette Syndrome in Children | Tourette Syndrome in Adolescence | Habit Reversal Training | TicUnited States
-
Tel Aviv Medical CenterUnknownTourette Syndrome in Children | Tourette Syndrome in Adolescence | Chronic Tic DisorderIsrael
-
Wake Forest University Health SciencesUniversity of Rochester; Tourette Association of AmericaRecruitingTourette Syndrome | Tics | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Tic Disorder, ChildhoodUnited States
-
University of MinnesotaCompletedTourette Syndrome | Tic Disorders | Tics | Tourette Syndrome in Children | Tourette Syndrome in Adolescence | Tic Disorder, Childhood | Tic, MotorUnited States
-
Max Planck Institute for Human Cognitive and Brain...Hannover Medical School; Leipzig University Medical CenterCompletedTourette Syndrome | Gilles de la Tourette SyndromeGermany
Clinical Trials on TEV-50717
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedCerebral Palsy, DyskineticUnited States, Denmark, Israel, Italy, Poland, Russian Federation, Spain, Ukraine, United Kingdom, Canada, Slovakia, Belgium
-
Teva Branded Pharmaceutical Products R&D, Inc.Nuvelution TS Pharma, Inc.CompletedTourette SyndromeUnited States, Canada, Denmark, Russian Federation, Serbia, Spain
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedCerebral Palsy, DyskineticUnited States, Italy, Russian Federation, Spain, Denmark, Israel, Poland, Ukraine, United Kingdom
-
Auspex Pharmaceuticals, Inc.CompletedTardive DyskinesiaUnited States, Czechia, Germany, Hungary, Poland, Slovakia
-
Teva Branded Pharmaceutical Products R&D, Inc.Nuvelution TS Pharma, Inc.TerminatedTourette SyndromeUnited States, Argentina, Australia, Canada, Colombia, Denmark, Hungary, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Serbia, Spain, Ukraine
-
Teva Branded Pharmaceutical Products R&D, Inc.Terminated
-
Verigraft ABRecruitingChronic Venous InsufficiencySpain
-
Teva Branded Pharmaceutical Products R&D, Inc.RecruitingCrohn Disease | Colitis, UlcerativeUnited States, Hungary, Poland, Czechia, Japan, Belgium, Spain, Bulgaria, France, Italy, Slovakia, Austria
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedCluster HeadacheUnited States, Australia, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedAsthmaUnited States, Bulgaria, Czechia, Germany, Poland